PointCross Life Sciences Opens New Office in Silver Spring, Maryland for Data Standardization of Nonclinical Studies
FOSTER CITY, CA, July 9, 2013 PRNewswire
FOSTER CITY, CA, July 9, 2013 PRNewswire
NIMS enables faster, deeper and more insightful regulatory review of nonclinical study data for safety signal detection and analysis
Nonclinical Study Data Specification (NSDS) for definition of a study before it begins, and ToxVision-as-a-software-Service to review studies after they are completed using the same visualization and analysis tools as in FDA’s NIMS are now available as a software subscription.
For pharma and biotech companies in Japan, this collaboration will ease the implementation of CDISC standards for electronic regulatory submissions which are a requirement by both the US FDA and Japanese PMDA
CAC EXICARE’s Location in Tokyo Japan and PointCross Life Sciences’s Location in Foster City, CA, August 24th, 2015 — PointCross Life Sciences and CAC EXICARE announced today that the companies have signed a partnership agreement to cooperate on providing services and technology solutions in Japan. As part of the strategic collaboration, CAC EXICARE will be PointCross Life Sciences partner of choice for the reselling, implementation, maintenance and support of PointCross Life Sciences electronic regulatory submission solutions including Data Standardization services. The two companies will also explore other future opportunities to collaborate on the PointCross solutions platform for drug research and development.
“With the FDA bindings guidance issued in Dec, 2014 and the Japanese Ministry of Health, Labour and Welfare issuing the technical notification for electronic data submission and a technical conformance guide in April 2015, pharma companies have only a short time span to implement solutions and processes that ensure compliance” said Suresh Madhavan, CEO of PointCross Life Sciences. “We are excited about partnering with CAC EXICARE to extend our reach in the Japanese market to help pharma companies comply with the new submission requirements.”
Koji Iwamoto, General Manager at BTO Development II, CAC EXICARE, said “FDA has announced submissions in sequence of nonclinical data in format of Standard for Exchange of Nonclinical Data (SEND) based on CDISC for studies that start after December of 2016. With the partnership with PointCross Life Sciences, which provides solution platforms offering SEND specialty services, we aim to expand our one-stop CDISC standardization services to the nonclinical studies industries. By undertaking all CDISC components in both clinical and nonclinical industries, we continue to devote ourselves to reducing the burden on pharmaceutical companies.”
PointCross Life Sciences provides the life sciences industry with data management, analytics and visualization solutions that reduce risks, improve data quality, shorten time to market, and generate better insights from R&D and regulatory data. We are a strategic solution provider to the FDA and to several major Biopharma companies. PointCross was recognized in 2013 as one of Gartner’s Cool Vendors in Life Sciences.
Contact
Ryan Brown, Senior Vice President
PointCross Life Sciences, Inc.
1291 E. Hillsdale Blvd., Suite 304
Foster City, CA 94404
ryan.brown@pointcross.com
CAC EXICARE is a solutions provider that supports pharmaceutical companies in both contract services and IT systems solutions. From drug discovery and non-clinical activities to post-marketing surveillance, we strongly support all the various processes of the pharmaceutical industry with the best use of IT. We meet the client needs for supports on global business by various activities with our overseas offices. Alliances with domestic and overseas CRO and SMO as well as IT & BPO vendors lead to a strong synergetic effect to respond quickly and flexibly to meet client needs.
CAC EXICARE Website:http://www.exicare.com
Contact
Hiroshi Watanabe
CAC EXICARE Corporation
24-1, Nihonbashi-Hakozakicho, Chuo-ku,
Tokyo 103-0015
+81-3-5623-4676
For biopharma companies, this collaboration will streamline the flow of high quality CDISC SEND standardized data for regulatory submissions required by the FDA and to serve sponsor R&D needs
FOSTER CITY, CA, March 11, 2013 PRNewswire
We are excited to bring you a revamped blog at PointCross, where will be frequently sharing blog posts penned by industry leaders on their perspective in the biotechnology and pharmaceutical markets.
PointCross Life Sciences Inc. delivers proven technology to support drug development through a suite of non-clinical and clinical
offerings.
1291 E. Hillsdale Blvd, Suite 304
Foster City, California 94404 USA
+1 (866) 468-1900
get_started@pointcross.com
© Copyright PointCross Life Sciences.